Fig. 5.

The mutational processes are associated with somatic copy number status and genetic burden of CDC27. The activity of the “NpCpG” (a) and “AID/APOBEC-2” (b) signature is associated with the somatic copy number amplification of CDC27. The FDR is based on the adjusted Wilcoxon rank-sum test P values. The activity of the “NpCpG” (c) and “AID/APOBEC-2” (d) signature is associated with the genetic burden of CDC27. The FDR is based on adjusted SKAT P values, with the effects of the age, the clinical stage and ancestry being corrected. The effects of the somatic copy number amplification and the genetic burden of CDC27 on the activity of the “NpCpG” signature (e) and the “AID/APOBEC-2” signature (f) are shown with other clinical features. The P values are based on multivariate linear regression analysis: *P < 0.05, **P < 0.01, ***P < 0.001